Immune effects of Lactobacillus casei Shirota in treated HIV-infected patients with poor CD4+ T-cell recovery.
- 2020-03-01
- RCT · n = 48
- AIDS (London, England) 34(3)
- Simone de Barros Tenore
- Vivian Iida Avelino-Silva
- Priscilla Ramos Costa
- Lucas M Franco
- Ester Cerdeira Sabino
- Jorge Kalil
- Natalia Barros Cerqueira
- Zelinda Nakagawa
- Esper Georges Kallas
- PubMed: 31714353
- DOI: 10.1097/qad.0000000000002420
- High evidence
- Clinical
Median change in CD4+/CD8+ ratio at week 6 compared with baseline was 0 (IQR -0.04 to 0.05) in the active intervention arm and -0.01 in the placebo arm (P = 0.671). At week 12, the change in CD4+/CD8+ ratio was higher in the active product group compared with placebo (respectively 0.07 and 0.01), but this difference failed to reach statistical significance (P = 0.171).
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- daily oral use